Cost cutting is Novartis' key to sustaining high R&D spending

04/3/2011 | Wall Street Journal, The

Unlike competitors, Novartis uses cost reduction to keep its funding level for research and development "at the top of the industry," said CEO Joe Jimenez. He is optimistic about the company's ability to generate strong sales growth despite competition from generics. "We have a strategy that can lead us to grow over the next five years despite patent losses and drug price cuts," he said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations